HIGHLIGHTS
- who: Qian Chen from the Shanghai Pulmonary Hospital, China Tongji University, China have published the research: Features of patients with advanced EGFR-mutated non-small cell lung cancer benefiting from immune checkpoint inhibitors, in the Journal: (JOURNAL)
- what: This study was designed to investigate the efficacy of ICIs in patients with EGFR-mutated NSCLC. In the study , data from EGFR-mutated NSCLC patients receiving ICIs (anti-PD-1 or anti-PD-L1, with or without antiCTLA-4) were collected, and 114 patients with PD-L1 expression were finally identified from three studies. The authors focused . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.